SMPD3 and Parkinson disease: In agreement with this hypothesis, we demonstrate here that acute treatment with an nSMase2 inhibitor, DDL-112, affects EV release in the Tg more than in NTg mice (Additional file 1: Fig S1), decreases levels of αSyn aggregates in the SN, and improves motor functions in a PD mouse model.